Group Wants Retraction of Study Raising Testosterone Therapy Concerns
Last November, a study published in the Journal of the American Medical Association (JAMA) found that testosterone therapy use was associated with an increased risk of stroke, heart attack, and death. The JAMA study was one of two that prompted the Food and Drug Administration to investigate the link between low-T drugs and cardiovascular risks. […]
Pentagon report: Navy Yard shooting could have been stopped
The Department of Defense recently released the results of its investigation into the prior military and employment history of Navy Yard shooter Aaron Alexis. Managers, co-workers, and others who interacted with Alexis voiced concerns about his mental health before the Sept. 16, 2013, shooting that left 12 people dead. The report many problems with the […]
General Motors sued by customers over ignition switch defect
The Cochran Firm, D.C. investigating product liability, wrongful death, and injury claims General Motors recently recalled 1.6 million cars due to problems with the ignition switch turning off while the vehicles are running. This product defect can endanger car passengers because air bags and power brakes and steering are disabled when the cars turn off. […]
MD House of Delegates Passes Law Targeting Distracted Drivers
The Maryland House of Delegates recently approved a law that allows judges to impose one-year jail sentences on drivers who negligently or seriously injure someone while texting or talking on a cellphone. The legislation, known as “Jake’s Law,” provides tougher penalties for distracted drivers who cause serious accidents while using their cell phone. The law […]
Axiron Fined for Illegally Promoting Testosterone Replacement Therapy
Eli Lilly and Company is under fire in Australia for illegally promoting its low-T testosterone gel Axiron. Australian authorities levied a $250,000 fine against the Indiana-based pharmaceutical giant for distributing a brochure about Axiron that encourage patients on testosterone replacement therapy to ask their doctors to switch to Axiron. Although the brochure itself was compliant […]
